Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Cell Biology,Oncology
Reference11 articles.
1. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
2. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
3. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
4. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
5. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in Melanoma;Cancers;2024-08-22
2. Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanoma;2024-08-06
3. The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib;FEBS Letters;2024-07-08
4. A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way;European Journal of Pharmacology;2024-04
5. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity;Cancer Cell;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3